FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4256366275> ?p ?o ?g. }

• W4256366275 endingPage "4051" @default.
• W4256366275 startingPage "4051" @default.
• W4256366275 abstract "4051 Background: Paclitaxel and capecitabine, which have distinct mechanisms of action and toxicity profiles, showed considerable single-agent activity in gastric cancer. Synergistic interaction between these two drugs was also suggested by taxane-induced upregulation of thymidine phosphorylase. Therefore, we evaluated antitumor activity and toxicities of paclitaxel and capecitabine combination in patients with advanced gastric cancer (AGC) as a first-line therapy. Methods: Patients with histologically confirmed AGC with unresectable or metastatic diseases, measurable lesions, PS 0–2, age between 18 and 75, and no contraindication to chemotherapy were eligible in this study. Prior adjuvant chemotherapy finished at least 6 months before enrollment was allowed. Treatment included capecitabine 825 mg/m2 p.o. twice daily on days 1–14 and paclitaxel 175 mg/m2 i.v. on day 1 every 3 weeks until disease progression or unacceptable toxicities. Results: Between June 2002 and December 2003, total 40 pts were enrolled in this study. The median age was 57.5 years (range, 38–73). Twenty-nine pts were male. Nine pts had recurrent disease after previous curative gastrectomy and 8 had previous adjuvant chemotherapy. After a median 4 (range, 1–9) cycles of chemotherapy, thirty-four pts were evaluable for toxicity and 33 pts for response (6 pts too early for evaluation, 1 pt loss to follow-up). In intention-to-treat analysis, the overall response rate was 52.9% (95% C.I., 36.2–69.6%), including 0 CR, 18 PRs, 9 SDs, and 6 PDs. After a median follow-up of 8.6 months (range, 0.9–17.9), median time to progression was 5.3 months (95% C.I., 3.6–6.9) and median overall survival was 14.6 months (95% C.I., 8.5–20.7). The actual dose intensity was well maintained over 95% of planned during the first 4 cycles in both drugs. Commonly observed grade 3/4 adverse events were neutropenia (41.1% of patients), hand-foot syndrome (11.8%), arthralgia (8.8%). There was no neutropenic fever or treatment-related death. Conclusions:Paclitaxel and capecitabine combination chemotherapy was active and highly tolerable as a first-line therapy for AGC. No significant financial relationships to disclose." @default.
• W4256366275 created "2022-05-12" @default.
• W4256366275 creator A5000589318 @default.
• W4256366275 creator A5000809998 @default.
• W4256366275 creator A5017042566 @default.
• W4256366275 creator A5022453705 @default.
• W4256366275 creator A5023085446 @default.
• W4256366275 creator A5023457705 @default.
• W4256366275 creator A5036219593 @default.
• W4256366275 creator A5037636747 @default.
• W4256366275 creator A5038691490 @default.
• W4256366275 creator A5066419662 @default.
• W4256366275 date "2004-07-15" @default.
• W4256366275 modified "2023-09-27" @default.
• W4256366275 title "A phase II study of paclitaxel and capecitabine combination chemotherapy in patients with advanced gastric cancer as a first-line therapy" @default.
• W4256366275 doi "https://doi.org/10.1200/jco.2004.22.14_suppl.4051" @default.
• W4256366275 hasPublicationYear "2004" @default.
• W4256366275 type Work @default.
• W4256366275 citedByCount "5" @default.
• W4256366275 crossrefType "journal-article" @default.
• W4256366275 hasAuthorship W4256366275A5000589318 @default.
• W4256366275 hasAuthorship W4256366275A5000809998 @default.
• W4256366275 hasAuthorship W4256366275A5017042566 @default.
• W4256366275 hasAuthorship W4256366275A5022453705 @default.
• W4256366275 hasAuthorship W4256366275A5023085446 @default.
• W4256366275 hasAuthorship W4256366275A5023457705 @default.
• W4256366275 hasAuthorship W4256366275A5036219593 @default.
• W4256366275 hasAuthorship W4256366275A5037636747 @default.
• W4256366275 hasAuthorship W4256366275A5038691490 @default.
• W4256366275 hasAuthorship W4256366275A5066419662 @default.
• W4256366275 hasConcept C121608353 @default.
• W4256366275 hasConcept C126322002 @default.
• W4256366275 hasConcept C143998085 @default.
• W4256366275 hasConcept C2776694085 @default.
• W4256366275 hasConcept C2777292972 @default.
• W4256366275 hasConcept C2777909004 @default.
• W4256366275 hasConcept C31760486 @default.
• W4256366275 hasConcept C526805850 @default.
• W4256366275 hasConcept C71924100 @default.
• W4256366275 hasConceptScore W4256366275C121608353 @default.
• W4256366275 hasConceptScore W4256366275C126322002 @default.
• W4256366275 hasConceptScore W4256366275C143998085 @default.
• W4256366275 hasConceptScore W4256366275C2776694085 @default.
• W4256366275 hasConceptScore W4256366275C2777292972 @default.
• W4256366275 hasConceptScore W4256366275C2777909004 @default.
• W4256366275 hasConceptScore W4256366275C31760486 @default.
• W4256366275 hasConceptScore W4256366275C526805850 @default.
• W4256366275 hasConceptScore W4256366275C71924100 @default.
• W4256366275 hasIssue "14_suppl" @default.
• W4256366275 hasLocation W42563662751 @default.
• W4256366275 hasOpenAccess W4256366275 @default.
• W4256366275 hasPrimaryLocation W42563662751 @default.
• W4256366275 hasRelatedWork W181195935 @default.
• W4256366275 hasRelatedWork W2033897338 @default.
• W4256366275 hasRelatedWork W2046284161 @default.
• W4256366275 hasRelatedWork W2085123446 @default.
• W4256366275 hasRelatedWork W2160763249 @default.
• W4256366275 hasRelatedWork W2411149337 @default.
• W4256366275 hasRelatedWork W2750041927 @default.
• W4256366275 hasRelatedWork W3041235120 @default.
• W4256366275 hasRelatedWork W84951532 @default.
• W4256366275 hasRelatedWork W2182401377 @default.
• W4256366275 hasVolume "22" @default.
• W4256366275 isParatext "false" @default.
• W4256366275 isRetracted "false" @default.
• W4256366275 workType "article" @default.